Haya Therapeutics

Series A round led by Sofinnova Partners and Earlybird Venture Capital with syndicate including Eli Lilly and Company Funds to advance clinical development of heart failure lead candidate and expand platform targeting the regulatory genome ‍LAUSANNE, Switzerland and SAN DIEGO, USA – May 8, 2025 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory … Read more

Former Exscientia executive who helped build the company and facilitate its merger with Recursion Pharmaceuticals joins to accelerate HAYA’s Non-dilutive funding of 1.5M CHF will be used to develop a novel therapy targeting cancer-associated fibroblast-specific long non-coding RNA (lncRNA)‍ LAUSANNE, Switzerland and SAN DIEGO, USA – Feb. 12, 2025 – HAYA Therapeutics, SA, a biotechnology company … Read more

Working towards a crucial breakthrough in the way we treat disease: HAYA Therapeutics aims to revolutionise patients treatments by focusing on Dark Genome-derived RNAs, now recognised as the ‹Regulatory Genome› RNAs. Thanks to its innovative approach, the company has attracted the attention of American pharmaceutical giant Eli Lilly. HAYA Therapeutics, which is supported by Innosuisse, is capitalising … Read more

This episode was sponsored by ⁠smzh⁠, your independent go-to partner in all matters relating to finance. About Samir Ounzain: ⁠Samir Ounzain⁠ is the co-founder and CEO of ⁠HAYA Therapeutics⁠, a precision medicines company targeting the regulatory genome for cardiovascular diseases, fibrosis and cancer. He holds a PhD from the University of Leicester and was previously a researcher at … Read more

HAYA Therapeutics is using its unparalleled regulatory genome atlas and innovative proprietary platform to identify novel long non-coding RNAs and develop drug candidates that return diseased cells back to healthy states. Heart failure and many other common and chronic diseases that have a huge impact on society can be driven by lifestyle-related risk factors. A … Read more

LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. … Read more

LAUSANNE, Switzerland and SAN DIEGO – July 15, 2024 – HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO). With over 25 years of experience in health technology and healthcare sectors, Eric joins HAYA’s team in … Read more

LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. … Read more

HAYA rises to the top: The Vaud-based startup ranks first at the TOP 100 Swiss Startup Award 2023. The biotech company leverages the power of the dark genome to develop precise and potent RNA therapies for reprogramming disease-driving cell states. HAYA was founded in 2019 by Samir Ounzain (CEO) and Daniel Blessing (CTO) and ranked … Read more